drugset / Trial / NCT02641353

Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension

NCT02641353

Phase 1 Completed 34 enrolled Amgen
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to assess how much of apremilast is found in the blood unchanged when administered as an oral suspension compared to when it is administered as a tablet formulation. The effect of food on apremilast oral suspension will also be evaluated. In addition, information on the safety and tolerability of apremilast will be obtained.

Timeline

Start
2016-01-05
Primary completion
2016-02-27
Completion
2016-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Apremilast Small molecule 30 mg Oral

Indications

No indication recorded.